Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Oncol. May 10, 2013; 4(2): 52-57
Published online May 10, 2013. doi: 10.5306/wjco.v4.i2.52
Published online May 10, 2013. doi: 10.5306/wjco.v4.i2.52
Non-AIDS-related Kaposi's sarcoma: A single-institution experience
Pasquale Rescigno, Rossella Di Trolio, Carlo Buonerba, Piera Federico, Davide Bosso, Antonella Virtuoso, Michela Izzo, Tania Policastro, Luca Vaccaro, Francesco Perri, Elide Matano, Sabino De Placido, Giovannella Palmieri, Giuseppe Di Lorenzo, Genitourinary Cancer Section and Rare-Cancer Center, Medical Oncology Division, University Federico II, 80131 Napoli, Italy
Gaia De Fata, Gianfranco Cimmino, Mario Delfino, Department of Dermatology, University Federico II of Naples, 80131 Napoli, Italy
Author contributions: Rescigno P, Di Trolio R and Di Lorenzo G contributed to the conception and design; Di Trolio R, Buonerba C, De Fata G, Federico P, Bosso D, Virtuoso A, Izzo M, Policastro T, Vaccaro L, Cimmino G, Perri F, Matano E, Delfino M and Palmieri G contributed to the acquisition of data; Buonerba C performed the statistical analysis; Rescigno P, Buonerba C, De Placido S and Di Lorenzo G contributed to drafting and revising the article; all authors approved the final version for publication.
Correspondence to: Giuseppe Di Lorenzo, MD, PhD, Genitourinary Cancer Section and Rare-Cancer Center, Medical Oncology Division, University Federico II, Via S. Pansini 5, 80131 Napoli, Italy. giuseppedilorenzoncol@hotmail.com
Telephone: +39-81-7463660 Fax: +39-81-7463660
Received: February 21, 2013
Revised: March 29, 2013
Accepted: April 9, 2013
Published online: May 10, 2013
Processing time: 88 Days and 5.2 Hours
Revised: March 29, 2013
Accepted: April 9, 2013
Published online: May 10, 2013
Processing time: 88 Days and 5.2 Hours
Core Tip
Core tip: Non-acquired immunodeficiency syndrome (AIDS)-related Kaposi’s sarcoma (KS) is usually relatively benign, with an indolent disease course. It appears to be highly responsive to a wide variety of chemotherapy agents, including pegylated liposomal doxorubicin, vinca-alkaloids, etoposide and taxanes. However, factors predictive of progression-free survival are lacking. In our series of 32 patients with non-AIDS-related KS, we showed that presence of nodular lesions (vs macular lesions only) was associated with a 3-fold increased risk of progression. If confirmed by further studies, such a finding may be useful to improve the therapeutic strategy for this disease at the individual level.